Atlas Trials

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Clinical trial NCT00171223 · COMPLETED

Trial details

NCT number
NCT00171223
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Start date
1999-12-06
Primary completion
2013-11-29
Enrollment
532

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.